LCTX vs. LLY
Compare and contrast key facts about Lineage Cell Therapeutics, Inc. (LCTX) and Eli Lilly and Company (LLY).
Performance
LCTX vs. LLY - Performance Comparison
Loading graphics...
LCTX vs. LLY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
LCTX Lineage Cell Therapeutics, Inc. | -5.39% | 232.34% | -53.90% | -6.84% | -52.24% | 39.20% | 97.75% | -2.52% | -51.46% | -40.44% |
LLY Eli Lilly and Company | -14.27% | 40.25% | 33.30% | 60.91% | 34.26% | 66.08% | 31.04% | 16.14% | 40.45% | 17.83% |
Fundamentals
LCTX:
$363.58M
LLY:
$825.96B
LCTX:
-$0.28
LLY:
$22.96
LCTX:
24.87
LLY:
12.68
LCTX:
8.39
LLY:
31.13
LCTX:
$14.56M
LLY:
$65.18B
LCTX:
$14.40M
LLY:
$54.62B
LCTX:
-$47.23M
LLY:
$27.94B
Returns By Period
In the year-to-date period, LCTX achieves a -5.39% return, which is significantly higher than LLY's -14.27% return. Over the past 10 years, LCTX has underperformed LLY with an annualized return of -4.69%, while LLY has yielded a comparatively higher 30.92% annualized return.
LCTX
- 1D
- 7.48%
- 1M
- -17.71%
- YTD
- -5.39%
- 6M
- -6.51%
- 1Y
- 249.87%
- 3Y*
- 1.75%
- 5Y*
- -8.47%
- 10Y*
- -4.69%
LLY
- 1D
- 3.74%
- 1M
- -12.57%
- YTD
- -14.27%
- 6M
- 20.93%
- 1Y
- 12.19%
- 3Y*
- 39.90%
- 5Y*
- 39.16%
- 10Y*
- 30.92%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
LCTX vs. LLY — Risk / Return Rank
LCTX
LLY
LCTX vs. LLY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Lineage Cell Therapeutics, Inc. (LCTX) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| LCTX | LLY | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 3.27 | 0.29 | +2.98 |
Sortino ratioReturn per unit of downside risk | 3.67 | 0.69 | +2.98 |
Omega ratioGain probability vs. loss probability | 1.39 | 1.10 | +0.30 |
Calmar ratioReturn relative to maximum drawdown | 8.50 | 0.42 | +8.08 |
Martin ratioReturn relative to average drawdown | 20.60 | 1.02 | +19.57 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| LCTX | LLY | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 3.27 | 0.29 | +2.98 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.12 | 1.23 | -1.34 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.06 | 1.04 | -1.10 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.02 | 0.56 | -0.58 |
Correlation
The correlation between LCTX and LLY is 0.10, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
LCTX vs. LLY - Dividend Comparison
LCTX has not paid dividends to shareholders, while LLY's dividend yield for the trailing twelve months is around 0.68%.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
LCTX Lineage Cell Therapeutics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 8.66% | 0.00% |
LLY Eli Lilly and Company | 0.68% | 0.56% | 0.67% | 0.78% | 1.07% | 1.23% | 1.75% | 1.96% | 1.94% | 2.46% | 2.77% | 2.37% |
Drawdowns
LCTX vs. LLY - Drawdown Comparison
The maximum LCTX drawdown since its inception was -99.31%, which is greater than LLY's maximum drawdown of -68.24%. Use the drawdown chart below to compare losses from any high point for LCTX and LLY.
Loading graphics...
Drawdown Indicators
| LCTX | LLY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.31% | -68.24% | -31.07% |
Max Drawdown (1Y)Largest decline over 1 year | -26.02% | -30.26% | +4.24% |
Max Drawdown (5Y)Largest decline over 5 years | -87.13% | -34.48% | -52.65% |
Max Drawdown (10Y)Largest decline over 10 years | -88.88% | -34.48% | -54.40% |
Current DrawdownCurrent decline from peak | -91.91% | -17.00% | -74.91% |
Average DrawdownAverage peak-to-trough decline | -78.63% | -19.25% | -59.38% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 10.74% | 12.39% | -1.65% |
Volatility
LCTX vs. LLY - Volatility Comparison
Lineage Cell Therapeutics, Inc. (LCTX) has a higher volatility of 18.45% compared to Eli Lilly and Company (LLY) at 9.04%. This indicates that LCTX's price experiences larger fluctuations and is considered to be riskier than LLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| LCTX | LLY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 18.45% | 9.04% | +9.41% |
Volatility (6M)Calculated over the trailing 6-month period | 42.39% | 26.21% | +16.18% |
Volatility (1Y)Calculated over the trailing 1-year period | 77.57% | 42.44% | +35.13% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 72.75% | 32.14% | +40.61% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 75.30% | 29.80% | +45.50% |
Financials
LCTX vs. LLY - Financials Comparison
This section allows you to compare key financial metrics between Lineage Cell Therapeutics, Inc. and Eli Lilly and Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
LCTX vs. LLY - Profitability Comparison
LCTX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Lineage Cell Therapeutics, Inc. reported a gross profit of 6.54M and revenue of 6.61M. Therefore, the gross margin over that period was 98.9%.
LLY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Eli Lilly and Company reported a gross profit of 16.41B and revenue of 19.29B. Therefore, the gross margin over that period was 85.1%.
LCTX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Lineage Cell Therapeutics, Inc. reported an operating income of -6.55M and revenue of 6.61M, resulting in an operating margin of -99.1%.
LLY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Eli Lilly and Company reported an operating income of 8.78B and revenue of 19.29B, resulting in an operating margin of 45.5%.
LCTX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Lineage Cell Therapeutics, Inc. reported a net income of 851.00K and revenue of 6.61M, resulting in a net margin of 12.9%.
LLY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Eli Lilly and Company reported a net income of 6.64B and revenue of 19.29B, resulting in a net margin of 34.4%.